Video

Dr. Ailawadhi on Potential Combination Strategies in Multiple Myeloma

Author(s):

Sikander Ailawadhi, MD

In Partnership With:

Sikander Ailawadhi, MD, discusses potential combination strategies with selinexor and belantamab mafodotin-blmf in multiple myeloma.

Sikander Ailawadhi, MD, professor of medicine, Division of Hematology/Oncology, Departments of Medicine and Cancer Biology, Mayo Clinic, discusses potential combination strategies with selinexor (Xpovio) and belantamab mafodotin-blmf (Blenrep) in multiple myeloma.

The approvals of selinexor and belantamab mafodotin have offered the potential to introduce novel combination strategies to the relapsed/refractory multiple myeloma paradigm. Moreover, combination regimens with these agents could include proteasome inhibitors, such as bortezomib (Velcade) or carfilzomib (Kyprolis), immunomodulatory agents, such as lenalidomide (Revlimid) or pomalidomide (Pomalyst), or monoclonal antibodies, such as daratumumab (Darzalex), explains Ailawadhi.

The question of which combinations will offer patients the most benefit remains unanswered, Ailawadhi says. In addition to clinical benefit, it’s important to look at the toxicity profile of the regimen to ensure that it does not compromise safety for patients, concludes Ailawadhi.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Tanios S. Bekaii-Saab, MD, FACP, of the Mayo Clinic
July 19th 2024

Complexity in GI Cancer: Questions Are Answered in Gastroesophageal Cancer, Remain in HCC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

C. Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center
July 19th 2024

Four-Drug Regimens Escalate the SOC for Newly Diagnosed Multiple Myeloma

Seth Wander, MD, PhD; Paolo Tarantino, MD; Daniel P. Petrylak, MD; Lionel A. Kankeu Fonkoua, MD; Solange Peters, MD, PhD; Edgardo Santos, MD, FACP, FCCP
October 9th 2023

Expert Insights on the United States Chemotherapy Shortage

Francisco Hernandez-Ilizaliturri, MD, of Roswell Park
July 17th 2024

Sequencing of Bispecific Antibodies vs CAR T-Cell Therapies is Dependent on Several Factors in DLBCL, Multiple Myeloma

Grzegorz S. Nowakowski, MD, of Mayo Clinic
July 12th 2024

Epcoritamab Shines in Third-Line Follicular Lymphoma With the Potential to Move into Earlier Lines